Topical nanocarriers for management of Rheumatoid Arthritis: A review - ScienceDirect
Biologics in rheumatoid arhritis (RA) | NRAS
Unresolved issues in biologic therapy for rheumatoid arthritis | Nature Reviews Rheumatology
Safety of biologic therapy in rheumatoid arthritis | Nature Reviews Rheumatology
Targeted Delivery Platforms for the Treatment of Multiple Sclerosis | Molecular Pharmaceutics
Biomedicines | Free Full-Text | Trends and Perspectives of Biological Drug Approvals by the FDA: A Review from 2015 to 2021
Nocebos in rheumatology: emerging concepts and their implications for clinical practice | Nature Reviews Rheumatology
Frontiers | Introducing Patterns of Variability for Overcoming Compensatory Adaptation of the Immune System to Immunomodulatory Agents: A Novel Method for Improving Clinical Response to Anti-TNF Therapies
Topical nanocarriers for management of Rheumatoid Arthritis: A review - ScienceDirect
Sulfasalazine Shortage: What to Do If You Can't Access Azulfidine
Which Biologic Therapies to Treat Active Rheumatoid Arthritis and When? - European Medical Journal
Biological Treatments for Rheumatoid Arthritis
Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2
U.S. International Trade Commission will investigate AbbVie claims that rival stole secrets - STAT
Do generics producers have what it takes to tackle complex and specialty drugs?
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update | Annals of the Rheumatic Diseases
About TRUXIMA® (rituximab-abbs) | Rheumatoid Arthritis | See Safety Info
Managing Rheumatic and Immunocompromised Diseases During COVID-19
Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay | Science Translational Medicine
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial - The Lancet
Treatment of Rheumatoid Arthritis with Biological Agents | IntechOpen
IJMS | Free Full-Text | Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence
